Please visit answersincme.com/TUD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the rationale for using novel add-on therapy in patients with pulmonary arterial hypertension (PAH) who are receiving stable background therapy, and the clinical implications of the latest evidence on these add-on therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of novel add-on therapies in patients with PAH who are receiving stable background therapy; Describe the latest clinical data for novel add-on therapies for patients with PAH who are on stable background therapy; and Outline multidisciplinary strategies for the optimal integration of novel add-on therapies into the existing treatment landscape for patients with PAH, as they become available.